

Christopher Goldring

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6678818/christopher-goldring-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32 papers	2,938 citations	19 h-index	33 g-index
33 ext. papers	3,350 ext. citations	8.9 avg, IF	4.49 L-index

#	Paper	IF	Citations
32	Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification. <i>Archives of Toxicology</i> , 2021 , 95, 2413-2430	5.8	0
31	The application of cytokeratin-18 as a biomarker for drug-induced liver injury. <i>Archives of Toxicology</i> , 2021 , 95, 3435-3448	5.8	4
30	Systems analysis of miRNA biomarkers to inform drug safety. <i>Archives of Toxicology</i> , 2021 , 95, 3475-3495	5.8	5
29	Transfer of hepatocellular microRNA regulates cytochrome P450 2E1 in renal tubular cells. <i>EBioMedicine</i> , 2020 , 62, 103092	8.8	3
28	Current Perspective: 3D Spheroid Models Utilizing Human-Based Cells for Investigating Metabolism-Dependent Drug-Induced Liver Injury.. <i>Frontiers in Medical Technology</i> , 2020 , 2, 611913	1.9	9
27	Stem cell models as an model for predictive toxicology. <i>Biochemical Journal</i> , 2019 , 476, 1149-1158	3.8	14
26	Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms. <i>Archives of Toxicology</i> , 2018 , 92, 557-569	5.8	30
25	Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop. <i>Regenerative Medicine</i> , 2018 , 13, 935-944	2.5	10
24	Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile. <i>Archives of Toxicology</i> , 2017 , 91, 439-452	5.8	72
23	Donor-Dependent and Other Nondefined Factors Have Greater Influence on the Hepatic Phenotype Than the Starting Cell Type in Induced Pluripotent Stem Cell Derived Hepatocyte-Like Cells. <i>Stem Cells Translational Medicine</i> , 2017 , 6, 1321-1331	6.9	11
22	Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. <i>Npj Regenerative Medicine</i> , 2017 , 2, 28	15.8	29
21	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017 , 65, 710-721	11.2	47
20	Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats. <i>Toxicology Letters</i> , 2016 , 258, 207-215	4.4	20
19	UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis. <i>Journal of Pathology</i> , 2016 , 238, 423-33	9.4	34
18	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. <i>Science Translational Medicine</i> , 2015 , 7, 298ra117	17.5	109
17	Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S95	4.0	3
16	MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity. <i>Toxicological Sciences</i> , 2015 , 144, 173-85	4.4	29

15	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models. <i>Applied in Vitro Toxicology</i> , 2015 , 1, 175-186	1.3	5
14	Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. <i>Free Radical Biology and Medicine</i> , 2015 , 78, 202-12	7.8	131
13	Predicting response to treatment for colorectal cancer: a review of relevant mechanisms and potential biomarkers. <i>Colorectal Cancer</i> , 2015 , 4, 85-95	0.8	
12	Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 389-400	6.9	82
11	MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 349-62	3.8	41
10	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. <i>Archives of Toxicology</i> , 2013 , 87, 1315-530	5.8	837
9	The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. <i>Biochemical Pharmacology</i> , 2013 , 85, 705-17	6	713
8	Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 885-96	3.8	61
7	Drug Bioactivation and Oxidative Stress 2012 , 1		
6	Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells. <i>Journal of Biological Chemistry</i> , 2012 , 287, 10556-10564	5.4	56
5	Assessing the safety of stem cell therapeutics. <i>Cell Stem Cell</i> , 2011 , 8, 618-28	18	175
4	Managing the challenge of chemically reactive metabolites in drug development. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 292-306	64.1	348
3	Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF-kappaB. <i>Biochemical Pharmacology</i> , 2010 , 80, 410-21	6	29
2	Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. <i>American Journal of Physiology - Cell Physiology</i> , 2006 , 290, C104-15	5.4	25
1	Plasticity in cell defence: access to and reactivity of critical protein residues and DNA response elements. <i>Journal of Experimental Biology</i> , 2006 , 209, 2337-43	3	4